<DOC>
	<DOCNO>NCT00860041</DOCNO>
	<brief_summary>RATIONALE : Gathering information time patient receive paclitaxel cancer may help doctor learn pain cause paclitaxel plan best treatment . PURPOSE : This clinical trial study acute pain cause paclitaxel patient cancer .</brief_summary>
	<brief_title>Acute Pain Caused Paclitaxel Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To describe incidence characteristic change pain related paclitaxel infusion several course patient receive paclitaxel weekly every 2-4 week without neurotoxic chemotherapy . - To investigate association paclitaxel-induced acute pain syndrome symptom eventual chemotherapy-induced neuropathy . - To perform exome-sequencing analysis identify genetic variant predict paclitaxel- induced peripheral neuropathy . - To identify clinical phenotype associate paclitaxel toxicity ( i.e. , acute pain syndrome neuropathy ) . - To explore whether evident difference result see majority Caucasian population minority population . OUTLINE : This multicenter study . Patients group accord paclitaxel dosing schedule ( weekly v every 2-4 week ) concurrent use neurotoxic agent ( yes v ) . Blood sample collect baseline correlative laboratory study , include genetic biomarker polymorphism study .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Planning receive paclitaxel IV ( exclude paclitaxel albuminstabilized nanoparticle formulation [ nabpaclitaxel ] ) accord one follow dose schedule : At least 175 mg/m^2 24 week interval ( course duration 2 , 3 , 4 week , respectively ) 7090 mg/m^2 weekly ( 3 4 week allow ) PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 6 month Able complete questionnaire ( alone assistance ) Willing provide require biological specimen No prior concurrent peripheral neuropathy ( diabetes cause ) No prior concurrent fibromyalgia PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior paclitaxel neurotoxic chemotherapy drug , include taxanes , platinum agent , vinca alkaloid , epothilones No concurrent neutrophil colonystimulating factor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>pain</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>